"Is Bristol-Myers Squibb (NYSE: BMY) ripe for a buyout?," asks growth expert Karim Rahemtulla. Here's an assessment from the investment director of Xcelerated Profits Report.
"I've predicted over the last several months that the larger pharmaceutical companies would be on the prowl for possible acquisitions.
"As it stands now, we probably haven't seen the last of such offers - and thanks to the previous two large mergers recently announced Merck acquiring Schering Plough and Pfizer buying Wyeth, many analysts are now speculating that Bristol-Myers Squibb could be next.
"Since we've foreseen that possibility for some time, we're hardly surprised, and expect shares to rise some on the speculation alone. So let me take the time to say that a potential acquisition is one of the worst reasons to buy a stock.
"If it happens, that's gravy. But you should always purchase stocks that you want to own, regardless of any potential suitors.
"With that word of caution aside, BMY is one of those prime companies that does have merit all on its own. The company is transforming itself into a biopharma company through acquisitions.
"It has a solid pipeline and pays a handsome 6% dividend, all marks of a company with a solid future. All of which leads us to the question: Who wouldn't want it?"
Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.
Closing Bell: Dubai sends jitters throughout the market (S, BBY)
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?
